| Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria CH Polman, SC Reingold, B Banwell, M Clanet, JA Cohen, M Filippi, ... Annals of neurology 69 (2), 292-302, 2011 | 8320 | 2011 |
| A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis CH Polman, PW O'Connor, E Havrdova, M Hutchinson, L Kappos, ... New England Journal of Medicine 354 (9), 899-910, 2006 | 3245 | 2006 |
| Rate of pregnancy-related relapse in multiple sclerosis C Confavreux, M Hutchinson, MM Hours, P Cortinovis-Tourniaire, ... New England Journal of Medicine 339 (5), 285-291, 1998 | 1567 | 1998 |
| Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis RJ Fox, DH Miller, JT Phillips, M Hutchinson, E Havrdova, M Kita, M Yang, ... New England Journal of Medicine 367 (12), 1087-1097, 2012 | 1136 | 2012 |
| Differential diagnosis of suspected multiple sclerosis: a consensus approach DH Miller, BG Weinshenker, M Filippi, BL Banwell, JA Cohen, ... Multiple Sclerosis Journal 14 (9), 1157-1174, 2008 | 737 | 2008 |
| Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post‐partum relapse S Vukusic, M Hutchinson, M Hours, T Moreau, P Cortinovis‐Tourniaire, ... Brain 127 (6), 1353-1360, 2004 | 592 | 2004 |
| Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing … E Havrdova, S Galetta, M Hutchinson, D Stefoski, D Bates, CH Polman, ... The Lancet Neurology 8 (3), 254-260, 2009 | 484 | 2009 |
| The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL PA Calabresi, G Giovannoni, C Confavreux, SL Galetta, E Havrdova, ... Neurology 69 (14), 1391-1403, 2007 | 344 | 2007 |
| MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS DH Miller, D Soon, KT Fernando, DG MacManus, GJ Barker, TA Yousry, ... Neurology 68 (17), 1390-1401, 2007 | 338 | 2007 |
| Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia N Fonknechten, D Mavel, P Byrne, CS Davoine, C Cruaud, D Boentsch, ... Human molecular genetics 9 (4), 637-644, 2000 | 299 | 2000 |
| Translation initiator EIF4G1 mutations in familial Parkinson disease MC Chartier-Harlin, JC Dachsel, C Vilariño-Güell, SJ Lincoln, F Leprêtre, ... The American Journal of Human Genetics 89 (3), 398-406, 2011 | 294 | 2011 |
| New perspectives in the natural history of multiple sclerosis H Tremlett, Y Zhao, P Rieckmann, M Hutchinson Neurology 74 (24), 2004-2015, 2010 | 294 | 2010 |
| Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody M Hutchinson, P Waters, J McHugh, G Gorman, S O’riordan, S Connolly, ... Neurology 71 (16), 1291-1292, 2008 | 285 | 2008 |
| The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL M Hutchinson, L Kappos, PA Calabresi, C Confavreux, G Giovannoni, ... Journal of neurology 256 (3), 405-415, 2009 | 234 | 2009 |
| Health‐related quality of life in multiple sclerosis: effects of natalizumab RA Rudick, D Miller, S Hass, M Hutchinson, PA Calabresi, C Confavreux, ... Annals of neurology 62 (4), 335-346, 2007 | 221 | 2007 |
| Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome S Hanein, E Martin, A Boukhris, P Byrne, C Goizet, A Hamri, A Benomar, ... The American Journal of Human Genetics 82 (4), 992-1002, 2008 | 200 | 2008 |
| Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases KP Bhatia, A Münchau, PD Thompson, M Houser, VS Chauhan, ... Journal of Neurology, Neurosurgery & Psychiatry 67 (1), 90-93, 1999 | 173 | 1999 |
| REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31 C Beetz, R Schüle, T Deconinck, KN Tran-Viet, H Zhu, BPH Kremer, ... Brain 131 (4), 1078-1086, 2008 | 172 | 2008 |
| Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns KET O'Rourke, M Hutchinson Multiple Sclerosis Journal 11 (1), 46-50, 2005 | 160 | 2005 |
| Natalizumab reduces visual loss in patients with relapsing multiple sclerosis LJ Balcer, SL Galetta, PA Calabresi, C Confavreux, G Giovannoni, ... Neurology 68 (16), 1299-1304, 2007 | 143 | 2007 |
Gavin GiovannoniBarts and The London School of Medicine and DentistryGeverifieerd e-mailadres voor giovannoni.net
